Cargando…

Eliminating endotoxin by polymyxin B hemoperfusion and/or continuous renal replacement therapy: should the focus be on timing, dosing, and type of renal epuration?

Detalles Bibliográficos
Autores principales:	Honore, Patrick M., De Bels, David, Redant, Sebastien, Spapen, Herbert D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408561/ https://www.ncbi.nlm.nih.gov/pubmed/30850912 http://dx.doi.org/10.1186/s13613-019-0512-0

Ejemplares similares

Efficacy of polymyxin B hemoperfusion in and beyond septic shock: is an “endotoxin severity score” needed?
por: Honore, Patrick M., et al.
Publicado: (2018)

Vitamin C Dosing During Continuous Renal Replacement Therapy: The Last Word is Not Said!
por: Honore, Patrick M., et al.
Publicado: (2019)

Endotoxin removal by polymyxin B: is it a question of dose or duration or both?
por: Honore, Patrick M., et al.
Publicado: (2019)

Dosing adjuvant vitamin C in critically ill patients undergoing continuous renal replacement therapy: We are not there yet!
por: Honore, Patrick M., et al.
Publicado: (2019)

Adjuvant vitamin C in cardiac arrest patients undergoing renal replacement therapy: an appeal for a higher high-dose
por: Honore, Patrick M., et al.
Publicado: (2018)

Neutrophil gelatinase-associated lipocalin elimination by renal replacement therapy: minding the membrane!
por: Honore, Patrick M., et al.
Publicado: (2016)

Validity of the relationship between mobility group box-1 protein and poor post–cardiac arrest neurological outcome during renal replacement therapy
por: Honore, Patrick M., et al.
Publicado: (2019)

Some metabolic issues should not be neglected when using citrate for continuous renal replacement therapy!
por: Jacobs, Rita, et al.
Publicado: (2015)

What a Clinician Should Know About a Renal Replacement Membrane?
por: Honore, Patrick M., et al.
Publicado: (2018)

Adsorption and caspofungin dosing during continuous renal replacement therapy
por: Honore, Patrick M., et al.
Publicado: (2019)

Is an EAA > 0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it?
por: Honore, Patrick M., et al.
Publicado: (2021)

Simplified method of regional citrate anticoagulation for continuous extra renal epuration
por: Cointault, O, et al.
Publicado: (2002)

Polymyxin B hemoperfusion in high endotoxin activity level septic shock patients
por: Monti, G, et al.
Publicado: (2008)

A Double Catheter Approach for Extracorporeal CO(2) Removal Integrated Within a Continuous Renal Replacement Circuit
por: Bels, David De, et al.
Publicado: (2018)

Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker?
por: Honore, Patrick M., et al.
Publicado: (2019)

No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure
por: Honore, Patrick M., et al.
Publicado: (2020)

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights
por: Honore, Patrick M., et al.
Publicado: (2019)

Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing
por: Honore, Patrick M., et al.
Publicado: (2020)

Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients
por: Cutuli, SL, et al.
Publicado: (2014)

Intertwining extracorporeal membrane oxygenation and continuous renal replacement therapy: sense or nonsense?
por: Jacobs, Rita, et al.
Publicado: (2015)

Polymyxin B-immobilized fiber column hemoperfusion has the ability of endotoxin removal during 24 hours
por: Mitaka, C, et al.
Publicado: (2012)

Who may benefit most from future vitamin D intervention trials: do not forget patients on continuous renal replacement therapy
por: Honore, Patrick M., et al.
Publicado: (2020)

Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction!
por: Honore, Patrick M., et al.
Publicado: (2015)

Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!
por: Honore, Patrick M., et al.
Publicado: (2016)

Polymyxin B hemoperfusion: a mechanistic perspective
por: Ronco, Claudio, et al.
Publicado: (2014)

Citrate: How to Get Started and What, When, and How to Monitor?
por: Honore, Patrick M., et al.
Publicado: (2018)

Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not
por: Honore, Patrick M., et al.
Publicado: (2020)

Endotoxin removal by hemoperfusion in septic shock
por: Adamik, B, et al.
Publicado: (2011)

‘Biomarking’ infection during continuous renal replacement therapy: still relevant?
por: Honore, Patrick M, et al.
Publicado: (2015)

Heparin-binding protein in sepsis: player! predictor! positioning?
por: Honore, Patrick M., et al.
Publicado: (2019)

Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation
por: Kushi, Hidehiko, et al.
Publicado: (2005)

Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors
por: Cantaluppi, Vincenzo, et al.
Publicado: (2008)

Effects of hemoperfusion and continuous renal replacement therapy on patient survival following paraquat poisoning
por: Wang, Yadong, et al.
Publicado: (2017)

Biomarker validity in the critically ill: all must face the (continuous) renal replacement challenge!
por: Honore, Patrick M., et al.
Publicado: (2015)

Higher colistin dose during continuous renal replacement therapy: look before leaping!
por: Honore, Patrick M., et al.
Publicado: (2015)

How levosimendan can improve renal function?
por: Honore, Patrick M., et al.
Publicado: (2019)

Early introduction of hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation
por: Kushi, H, et al.
Publicado: (2005)

More effective use of polymyxin-B hemoperfusion for nonoperation cases
por: Yahata, M, et al.
Publicado: (2014)

Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?
por: Honore, Patrick M, et al.
Publicado: (2015)

Is neutrophil gelatinase-associated lipocalin unaffected by convective continuous renal replacement therapy? Definitely … maybe
por: Honore, Patrick M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6ph2b6sqf22u1n7263ri09cjed